YOUR SEARCH FOR Text 77 RESULTS
1 of Total
Understanding Hidradenitis Suppurativa (HS) | Incyte Stories
… Kirby: Treatment approaches are tailored by a doctor based on each person's HS, other medical … the team taking care of someone with HS. Other specialists might help too, depending on the …
5 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Financial Results and Provides Updates on Key Clinical Programs October 31, 2023 at 7:00 AM … Beginning January 1, 2024 , Opzelura will be listed as a Preferred Brand on the CVS Caremark …
6 of Total
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Financial Results and Provides Updates on Key Clinical Programs April 30, 2024 at 7:00 AM EDT … and provides a status update on the Company’s clinical development portfolio. "In the first …
7 of Total
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Financial Results and Provides Updates on Key Clinical Programs May 4, 2021 at 8:00 AM EDT PDF … Myelofibrosis, polycythemia vera & GVHD: clinical pharmacology studies ruxolitinib + …
8 of Total
Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Financial Results and Provides Updates on Key Clinical Programs May 2, 2023 at 7:00 AM EDT PDF … and provides a status update on the Company’s clinical development portfolio. "Our first …
9 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Financial Results and Provides Updates on Key Clinical Programs July 30, 2024 at 7:00 AM EDT … increased R&D focus on innovative high impact clinical programs; acquisition of Escient …
10 of Total
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Financial Results and Provides Updates on Key Clinical Programs May 3, 2022 at 7:00 AM EDT PDF … and provides a status update on the Company’s clinical development portfolio. “Our …